Page last updated: 2024-10-16

gamma-aminobutyric acid and Bilateral Headache

gamma-aminobutyric acid has been researched along with Bilateral Headache in 39 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

ExcerptRelevanceReference
"This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy."9.10Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"Despite the inherent limitations of such a small open trial, the authors concluded that ratings of excellent and good by two thirds of this population of patients with chronic daily headache should encourage the setup of a large double-blind, multicentric, placebo-controlled trial of low doses of gabapentin for chronic daily headache."9.09Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
"To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache."9.09Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
"Comorbid conditions are common among patients with fibromyalgia and their presence is not associated with altered pregabalin efficacy."8.86Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010)
"Patients diagnosed with fibromyalgia according to the American College of Rheumatology criteria, randomized to placebo or 300, 450, or 600 mg/day pregabalin, and with ≥ 1 postbaseline pain score were included."8.86Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."8.81Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Headache is the most prevalent symptom of acute mountain sickness."6.73Low-dose gabapentin in treatment of high-altitude headache. ( Gorouhi, F; Jafarian, S; Lotfi, J; Salimi, S, 2007)
"Gabapentin was effective for the prevention of HAH and had satisfactory tolerability."6.73Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial. ( Abolfazli, R; Gorouhi, F; Jafarian, S; Lotfi, J; Rezaie, S, 2008)
" During 2- and 6-week titration periods, respectively, GBP dosage reached 1,800 mg/day, and LTG, 150 mg/day."6.70Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"Gabapentin has been successfully used for a variety of chronic pain conditions and therefore may be of use in the treatment of chronic headache."6.69Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
"Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia."6.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
" A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks."6.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
" However, narcotics can have significant adverse effects."5.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"GBP appears to be relatively safe and tolerable in SAH patients with headache and may be a useful narcotic-sparing agent to prevent narcotics-associated complications, such as gastrointestinal immobility, ileus, and constipation."5.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
" GBP dosing was rapidly escalated within days of SAH up to a median of 1,200 mg/day, with a range of 300 mg three times a day to 900 mg three times a day."5.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"Severe headache was observed in all SAH patients."5.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"Headache after aneurysmal subarachnoid hemorrhage (SAH) is very common and is often described as the "worst headache imaginable."5.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"Gabapentin (Neurontin) was then started with improvement at 1800 mg per day."5.31SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000)
"This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy."5.10Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"Despite the inherent limitations of such a small open trial, the authors concluded that ratings of excellent and good by two thirds of this population of patients with chronic daily headache should encourage the setup of a large double-blind, multicentric, placebo-controlled trial of low doses of gabapentin for chronic daily headache."5.09Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
"To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache."5.09Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
"Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses."5.08High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998)
"Patients diagnosed with fibromyalgia according to the American College of Rheumatology criteria, randomized to placebo or 300, 450, or 600 mg/day pregabalin, and with ≥ 1 postbaseline pain score were included."4.86Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010)
"Comorbid conditions are common among patients with fibromyalgia and their presence is not associated with altered pregabalin efficacy."4.86Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010)
"In recent years, anticonvulsant drugs (AEDs) have been considered promising drugs in the prevention of migraine and other forms of headache, based on their action on the metabolism of gamma-aminobutyric acid (GABA) and glutamate."4.82Antiepileptic drugs in the treatment of chronic headaches. ( Agostoni, E; Frigerio, R; Santoro, P, 2003)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."4.81Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Gabapentin (GBP) is a antiepileptic drug (AED) indicated as adjunct therapy for treatment of partial seizures, with and without secondary generalization, in patients 12 and older with epilepsy."4.80Gabapentin. ( Morris, GL, 1999)
"Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin."3.72[Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003)
"Gamma-Aminobutyric acid (GABA) levels in cerebrospinal fluid were measured in seven patients with tension headache and 12 patients with migraine."3.65Cerebrospinal fluid gamma aminobutyric acid levels in migraine. ( Achar, VS; Bartosh, K; Chabi, E; Meyer, JS; Welch, KM, 1975)
" XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily) was well absorbed (>68%, based on urinary recovery of gabapentin), converted rapidly to gabapentin, and provided dose-proportional exposure, whereas absorption of oral gabapentin declined with increasing doses to <27% at 1200 mg."2.73Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ( Canafax, DM; Cundy, KC; Luo, W; Moors, TL; Sastry, S; Zou, J, 2008)
"Gabapentin was effective for the prevention of HAH and had satisfactory tolerability."2.73Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial. ( Abolfazli, R; Gorouhi, F; Jafarian, S; Lotfi, J; Rezaie, S, 2008)
"Headache is the most prevalent symptom of acute mountain sickness."2.73Low-dose gabapentin in treatment of high-altitude headache. ( Gorouhi, F; Jafarian, S; Lotfi, J; Salimi, S, 2007)
" XP13512 may therefore provide more predictable gabapentin exposure and decreased dosing frequency."2.73Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ( Canafax, DM; Cundy, KC; Luo, W; Moors, TL; Sastry, S; Zou, J, 2008)
" During 2- and 6-week titration periods, respectively, GBP dosage reached 1,800 mg/day, and LTG, 150 mg/day."2.70Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"Gabapentin doses >1,800 mg/day were as well tolerated as doses < or =1,800 mg/day and were not associated with more adverse events."2.69Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999)
"Gabapentin has been successfully used for a variety of chronic pain conditions and therefore may be of use in the treatment of chronic headache."2.69Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000)
" In six patients, including three taking 6000 mg daily, GBP concentrations continued to rise linearly at each dosage increment."2.69High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998)
"Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses."2.69High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998)
" Two analyses of adverse events are presented: tolerability and safety."2.69Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999)
" Within these 281 patients, two mutually exclusive groups were compared (a) those reporting adverse events at only < or =1,800 mg/day (low dose); and (b) those reporting adverse events at only >1,800 mg/day (high dose)."2.69Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999)
"Most of the reports of headache in GBS place it in the context of the posterior reversible encephalopathy syndrome (PRES) which is increasingly recognized as a likely dysautonomia-related GBS complication."2.52Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015)
"Gabapentin is a reasonable first-line choice, and opioid medications can be added for more severe pain but there are few clinical trials to inform specific recommendations."2.52Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015)
"Pediatric migraine can cause a significant impact on quality of life."2.45[Antiepileptic drugs for the prevention of pediatric migraine]. ( Cuvellier, JC, 2009)
"Neuropathic cranial pain, i."2.42Neuropathic cranial pain. ( Annovazzi, PO; Colombo, B; Comi, G, 2003)
" A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks."2.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia."2.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Gabapentin (GBP) is a antiepileptic drug (AED) indicated as adjunct therapy for treatment of partial seizures, with and without secondary generalization, in patients 12 and older with epilepsy."2.40Gabapentin. ( Morris, GL, 1999)
"Treatment outcomes for migraine and other chronic headache and pain conditions typically demonstrate modest results."1.62Increased GABA+ in People With Migraine, Headache, and Pain Conditions- A Potential Marker of Pain. ( Aguila, MR; Foster, S; Galloway, G; Leaver, AM; Ng, K; Oeltzschner, G; Peek, AL; Puts, NA; Rebbeck, T; Refshauge, K; Sterling, M, 2021)
"Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks."1.43Using a graphical risk tool to examine willingness to take migraine prophylactic medications. ( Golding, AN; Houle, TT; Turner, DP, 2016)
"The map reflected 4 restricted areas of mechanical hyperalgesia confined just to the painful areas."1.42Pressure pain sensitivity map of multifocal nummular headache: a case report. ( Barón, J; Carreres, A; Cuadrado, ML; Fernández-de-Las-Peñas, C; Guerrero, AL; Herrero-Velázquez, S; Madeleine, P; Rodríguez, C; Rodríguez-Valencia, E; Ruiz, M, 2015)
"Treatment with gabapentin achieved complete remission."1.42Pressure pain sensitivity map of multifocal nummular headache: a case report. ( Barón, J; Carreres, A; Cuadrado, ML; Fernández-de-Las-Peñas, C; Guerrero, AL; Herrero-Velázquez, S; Madeleine, P; Rodríguez, C; Rodríguez-Valencia, E; Ruiz, M, 2015)
"Headache after aneurysmal subarachnoid hemorrhage (SAH) is very common and is often described as the "worst headache imaginable."1.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
" GBP dosing was rapidly escalated within days of SAH up to a median of 1,200 mg/day, with a range of 300 mg three times a day to 900 mg three times a day."1.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"GBP appears to be relatively safe and tolerable in SAH patients with headache and may be a useful narcotic-sparing agent to prevent narcotics-associated complications, such as gastrointestinal immobility, ileus, and constipation."1.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
" However, narcotics can have significant adverse effects."1.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"Severe headache was observed in all SAH patients."1.42Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015)
"Occipital neuralgia is an extracranial pain that may be confused with other headaches."1.33Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005)
"Carbamazepine (300 mg/d) was required for pain control."1.33Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005)
"SUNCT, a still relatively unknown headache syndrome, is characterized by attacks of periorbital pain with accompanying ipsilateral autonomic symptoms."1.32[Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003)
"Gabapentin (Neurontin) was then started with improvement at 1800 mg per day."1.31SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000)
"GABA was detected only during the migraine attack."1.25Cerebrospinal fluid gamma aminobutyric acid levels in migraine. ( Achar, VS; Bartosh, K; Chabi, E; Meyer, JS; Welch, KM, 1975)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.56)18.7374
1990's6 (15.38)18.2507
2000's21 (53.85)29.6817
2010's10 (25.64)24.3611
2020's1 (2.56)2.80

Authors

AuthorsStudies
Peek, AL1
Leaver, AM1
Foster, S1
Oeltzschner, G1
Puts, NA1
Galloway, G1
Sterling, M1
Ng, K1
Refshauge, K1
Aguila, MR1
Rebbeck, T1
Mah, L1
Hart, M1
Oshinsky, ML1
Murphy, AL1
Hekierski, H1
Cooper, M1
Simon, BJ1
Iwanowski, P1
Kozubski, W1
Losy, J1
Dhakal, LP1
Hodge, DO1
Nagel, J1
Nagal, J1
Mayes, M1
Richie, A1
Ng, LK1
Freeman, WD1
Rodríguez, C1
Herrero-Velázquez, S1
Ruiz, M1
Barón, J1
Carreres, A1
Rodríguez-Valencia, E1
Guerrero, AL1
Madeleine, P1
Cuadrado, ML1
Fernández-de-Las-Peñas, C1
Farmakidis, C1
Inan, S1
Milstein, M1
Herskovitz, S1
Turner, DP1
Golding, AN1
Houle, TT1
De Cesaris, F1
Fanciullacci, M1
Pietrini, U1
Anselmi, B1
Del Bene, E1
Cundy, KC1
Sastry, S1
Luo, W1
Zou, J1
Moors, TL1
Canafax, DM1
Cuvellier, JC1
Rossi, P1
Tassorelli, C1
Allena, M1
Ferrante, E1
Lisotto, C1
Nappi, G1
Bhadra, P1
Petersel, D1
Chen, WH1
Li, TH1
Lee, LH1
Huang, CC1
Brodie, MJ2
Chadwick, DW1
Anhut, H1
Otte, A1
Messmer, SL1
Maton, S1
Sauermann, W1
Murray, G1
Garofalo, EA1
Neumeier, S1
Brinkschmidt, T1
Jensen, U1
Burchell, BJ1
Agostoni, E1
Frigerio, R1
Santoro, P1
Colombo, B1
Annovazzi, PO1
Comi, G1
França, MC1
Costa, AL1
Maciel, JA1
Frediani, F1
Mourouzis, C1
Saranteas, T1
Rallis, G1
Anagnostopoulou, S1
Tesseromatis, C1
Wamsler, C1
Schürmann, S1
Dubbel, G1
Blankenburg, M1
Zernikow, B1
Trucco, M2
Mainardi, F1
Perego, G1
Zanchin, G1
Jafarian, S2
Gorouhi, F2
Salimi, S1
Lotfi, J2
Paech, MJ1
Goy, R1
Chua, S1
Scott, K1
Christmas, T1
Doherty, DA1
Abolfazli, R1
Rezaie, S1
Bigal, ME1
Hetherington, H1
Pan, J1
Tsang, A1
Grosberg, B1
Avdievich, N1
Friedman, B1
Lipton, RB1
Wilson, EA1
Sills, GJ1
Forrest, G1
García-Albea, E1
McLean, MJ1
Morrell, MJ1
Willmore, LJ1
Privitera, MD1
Faught, RE1
Holmes, GL1
Magnus-Miller, L1
Bernstein, P1
Rose-Legatt, A1
Gay, CT1
Morris, GL1
Graff-Radford, SB1
Fragoso, YD1
Carrazana, EJ1
Hurley, SC1
Welch, KM1
Chabi, E1
Bartosh, K1
Achar, VS1
Meyer, JS1
Kowa, H1
Shimomura, T1
Takahashi, K1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage[NCT04126408]40 participants (Actual)Interventional2020-01-13Completed
The Effect Of Transcutaneous Auricular Vagus Nerve Stimulation On Sports Performance And Physiological Parameters In Healthy Young Individuals: Randomized, Double-Blind Study[NCT04768738]46 participants (Actual)Interventional2020-02-01Completed
Nummular Headache Iberian Study on the Treatments and Outcomes in Real-World Setting[NCT05475769]98 participants (Anticipated)Observational2022-03-01Recruiting
A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia[NCT00230776]Phase 3740 participants Interventional2005-10-31Completed
A 13-week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia[NCT00645398]Phase 3751 participants (Actual)Interventional2004-09-30Completed
A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.[NCT00333866]Phase 3747 participants (Actual)Interventional2006-07-31Completed
A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451]Phase 4361 participants (Actual)Interventional2007-01-31Completed
Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859]Phase 450 participants (Anticipated)Interventional2010-04-30Completed
Preoperative Use of Pregabalin and Analgesia Levels After Laparoscopic Cholecystectomy[NCT01321801]50 participants (Actual)Interventional2009-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Scores at Week 14

FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14

InterventionUnits on a scale (Least Squares Mean)
Placebo-6.94
Pregabalin 300 mg-8.11
Pregabalin 450 mg-12.79
Pregabalin 600 mg-8.38

Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14)

Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.73
Pregabalin 300 mg-1.06
Pregabalin 450 mg-1.29
Pregabalin 600 mg-0.96

Change From Baseline in Mean Sleep Quality Score at Endpoint (Up to Week 14)

Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.94
Pregabalin 300 mg-1.42
Pregabalin 450 mg-1.72
Pregabalin 600 mg-1.95

Change From Baseline in Multidimensional Assessment of Fatigue (MAF) at Week 14

MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue). (NCT00333866)
Timeframe: Baseline, Week 14

InterventionUnits on a scale (Least Squares Mean)
Placebo-1.91
Pregabalin 300 mg-2.78
Pregabalin 450 mg-3.32
Pregabalin 600 mg-2.19

Change From Baseline in Pain Visual Analogue Scale (VAS) Scores at Week 14

Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain. (NCT00333866)
Timeframe: Baseline, Week 14

Interventionmm (Least Squares Mean)
Placebo-10.30
Pregabalin 300 mg-12.86
Pregabalin 450 mg-17.75
Pregabalin 600 mg-11.74

Percentage of Participants With Optimal Sleep Assessed Using MOS-SS

Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance. (NCT00333866)
Timeframe: Baseline, Week 14

InterventionPercentage of participants (Number)
Placebo30.8
Pregabalin 300 mg33.5
Pregabalin 450 mg44.0
Pregabalin 600 mg32.4

Total Daily Acetaminophen Dose

Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days). (NCT00333866)
Timeframe: Week 14

Interventionmg/day (Least Squares Mean)
Placebo460.65
Pregabalin 300 mg449.14
Pregabalin 450 mg508.53
Pregabalin 600 mg724.42

Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Subscale Scores at Week 14

FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14

,,,
InterventionUnits on a scale (Least Squares Mean)
FIQ Physical Impairment (n=183,184,179,186)FIQ Feel Good (n=182,184,178,183)FIQ Work Missed (n=182,181,178,184)FIQ Do Work (n=182,183,179,185)FIQ Pain (n=183,184,179,185)FIQ Fatigue (n=183,184,179,184)FIQ Rested (n=183,184,179,185)FIQ Stiffness (n=183,184,179,185)FIQ Anxiety (n=183,184,179,185)FIQ Depression (n=181,184,179,184)
Placebo-0.09-1.15-0.13-0.90-0.97-0.81-0.94-1.06-0.48-0.22
Pregabalin 300 mg-0.26-1.11-0.29-1.04-1.18-0.86-1.17-1.02-0.66-0.56
Pregabalin 450 mg-0.35-1.77-0.75-1.60-1.72-1.36-1.47-1.28-1.12-1.19
Pregabalin 600 mg-0.26-1.26-0.27-0.98-1.10-1.05-1.40-0.94-0.68-0.43

Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 14

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00333866)
Timeframe: Baseline, Week 14

,,,
InterventionUnits on a scale (Least Squares Mean)
HADS Anxiety (HADS-A) TotalHADS Depression (HADS-D) Total
Placebo-0.31-0.11
Pregabalin 300 mg-0.42-0.33
Pregabalin 450 mg-0.81-0.70
Pregabalin 600 mg-0.900.04

Change From Baseline in Medical Outcomes Study (MOS): Sub-scales at Week 14

Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute. (NCT00333866)
Timeframe: Baseline, Week 14

,,,
InterventionUnits on a scale (Least Squares Mean)
Sleep Disturbance (n=183,183,177,185)Snoring (n=172,174,174,177)Shortness of Breath, Headache (n=182,182,177,184)Quantity of Sleep (n=182,182,175,182)Sleep Adequacy (n=183,183,179,185)Somnolence (n=182,182,177,184)Overall Sleep Problem Index (n=181,181,174,184)
Placebo-5.99-0.03-0.670.417.62-0.10-4.83
Pregabalin 300 mg-13.181.17-9.620.6110.190.67-9.19
Pregabalin 450 mg-19.264.89-12.590.9116.760.61-13.07
Pregabalin 600 mg-18.705.87-9.910.7611.971.92-11.72

Change From Baseline in Short Form-36 (SF-36) Health Survey at Week 14

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning. (NCT00333866)
Timeframe: Baseline, Week 14

,,,
InterventionUnits on a scale (Least Squares Mean)
Physical Functioning (n=184,184,177,186)Physical Role Limitations (n=183,183,177,185)Emotional Role Limitations (n=183,183,177,185)Social Functioning (n=183,184,178,186)Mental Health (n=183,184,178,186)Bodily Pain (n=183,184,178,186)Vitality (n=183,184,178,186)General Health Perception (n=183,184,177,186)Mental Component Score (n=182,183,176,184)Physical Component Score (n=182,183,176,184)
Placebo4.644.01-2.310.75-1.674.954.150.94-1.272.47
Pregabalin 300 mg5.224.401.444.101.657.774.892.760.872.60
Pregabalin 450 mg6.635.503.935.764.2510.329.253.672.393.01
Pregabalin 600 mg4.135.031.563.602.417.537.292.211.352.34

Change From Baseline in Weekly Mean Sleep Quality Score

Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries. (NCT00333866)
Timeframe: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14

,,,
InterventionUnits on a scale (Least Squares Mean)
Week 1 (n=183,179,174,178)Week 2 (n=180,172,168,174)Week 3 (n=174, 164, 159,163)Week 4 (n=165,157,155,156)Week 5 (n=163, 150, 152,148)Week 6 (n=159,145,148,144)Week 7 (n=155,140,144,133)Week 8 (n=149,133,142,127)Week 9 (n=146,128,141,126)Week 10 (n=144,125,139,126)Week 11 (n=143,123,137,121)Week 12 (n=141,121,135,119)Week 13 (n=140,120,133,118)Week 14 (n=134,115,128,111)Overall (n=183,179,174,178)
Placebo-0.38-0.62-0.75-0.73-0.82-0.84-0.91-0.99-1.11-1.14-1.09-1.22-1.05-1.08-0.91
Pregabalin 300 mg-1.20-1.48-1.42-1.52-1.67-1.56-1.50-1.60-1.64-1.75-1.65-1.62-1.66-1.73-1.57
Pregabalin 450 mg-1.08-1.43-1.56-1.67-1.69-1.76-1.83-1.95-1.94-2.03-1.92-1.95-1.93-1.95-1.76
Pregabalin 600 mg-1.23-1.59-1.90-2.01-1.99-2.15-2.20-2.25-2.24-2.34-2.24-2.29-2.26-2.29-2.07

Patient Global Impression of Change (PGIC)

Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00333866)
Timeframe: Week 14

,,,
Interventionparticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Placebo743454311173
Pregabalin 300 mg134550289145
Pregabalin 450 mg16505527782
Pregabalin 600 mg2046412510103

58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment

(NCT00438451)
Timeframe: 58 weeks

Interventionproportion of participants (Mean)
Levetiracetam0.61
Carbamazepine0.46
Lamotrigine0.56

Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)

Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58

Interventionpercentage of participants (Number)
Levetiracetam43
Carbamazepine33
Lamotrigine38

Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)

Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30

Interventionpercentage of participants (Number)
Levetiracetam48
Carbamazepine39
Lamotrigine49

Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase

(NCT00438451)
Timeframe: 52 weeks

Interventionproportion of seizure-free days (Number)
Levetiracetam0.99
Carbamazepine0.99
Lamotrigine0.99

Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6

EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58

Interventionunits on a scale (Mean)
Levetiracetam26.0
Carbamazepine26.0
Lamotrigine25.4

The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)

"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks

Interventionnumber of seizures (Number)
Levetiracetam168
Carbamazepine131
Lamotrigine130

The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)

(NCT00438451)
Timeframe: over the whole duration of 58 weeks

Interventiondays (Median)
LevetiracetamNA
CarbamazepineNA
LamotrigineNA

Time to Drop Out

number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks

Interventiondays (Median)
LevetiracetamNA
Carbamazepine265
LamotrigineNA

Portland Neurotoxicity Scale (PNS) at V6

"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58

,,
Interventionunits on a scale (Mean)
Cognitive toxicity subscoreSomatomotor subscoreTotal Score
Carbamazepine27.311.438.7
Lamotrigine23.710.834.5
Levetiracetam22.210.532.7

QOLIE-31 (Quality Of Life In Epilepsy) Results at V6

The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit

,,
Interventionunits on a scale (Mean)
Seizure worryOverall quality of lifeEmotional well-beingEnergy/fatigueCognitive functioningMedication effectsSocial functioningTotal ScoreHealth Scale
Carbamazepine75.465.069.854.568.970.676.368.965.7
Lamotrigine75.067.167.459.868.072.676.769.167.5
Levetiracetam85.167.272.060.875.177.681.173.969.5

Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6

"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks

,,
Interventionparticipants (Number)
Without pathological findingsBorderlineImpaired
Carbamazepine341733
Lamotrigine311539
Levetiracetam381036

Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)

"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58

,,
Interventionparticipants (Number)
ImprovedUnchangedWorsened
Carbamazepine16568
Lamotrigine155313
Levetiracetam15616

Reviews

10 reviews available for gamma-aminobutyric acid and Bilateral Headache

ArticleYear
Gabapentin withdrawal: case report in an older adult and review of the literature.
    Journal of the American Geriatrics Society, 2013, Volume: 61, Issue:9

    Topics: Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Depression; Female; Gabapentin; gamm

2013
Headache and Pain in Guillain-Barré Syndrome.
    Current pain and headache reports, 2015, Volume: 19, Issue:8

    Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Guillain-Barre Sy

2015
[Antiepileptic drugs for the prevention of pediatric migraine].
    Revue neurologique, 2009, Volume: 165, Issue:12

    Topics: Adolescent; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Tolerance; Fructose; G

2009
Focus on therapy: hemicrania continua and new daily persistent headache.
    The journal of headache and pain, 2010, Volume: 11, Issue:3

    Topics: Amines; Analgesics; Celecoxib; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fructose; Gaba

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:17

    Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru

2010
Antiepileptic drugs in the treatment of chronic headaches.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24 Suppl 2

    Topics: Anticonvulsants; Chronic Disease; gamma-Aminobutyric Acid; Headache; Humans; Meta-Analysis as Topic

2003
Neuropathic cranial pain.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24 Suppl 2

    Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Anticonvulsants; Antidepressive Agents, Tric

2003
Anticonvulsant drugs in primary headaches prophylaxis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25 Suppl 3

    Topics: Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fruct

2004
Gabapentin.
    Epilepsia, 1999, Volume: 40 Suppl 5

    Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids;

1999
Lamotrigine update and its use in mood disorders.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:5

    Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids;

2002

Trials

8 trials available for gamma-aminobutyric acid and Bilateral Headache

ArticleYear
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:12

    Topics: Adult; Aged; Amines; Area Under Curve; Biological Availability; Capsules; Carbamates; Cross-Over Stu

2008
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
    Epilepsia, 2002, Volume: 43, Issue:9

    Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan

2002
Low-dose gabapentin in treatment of high-altitude headache.
    Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Altitude Sickness; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind

2007
A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery.
    Anesthesia and analgesia, 2007, Volume: 105, Issue:5

    Topics: Administration, Oral; Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Gynecologic Surgi

2007
A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery.
    Anesthesia and analgesia, 2007, Volume: 105, Issue:5

    Topics: Administration, Oral; Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Gynecologic Surgi

2007
A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery.
    Anesthesia and analgesia, 2007, Volume: 105, Issue:5

    Topics: Administration, Oral; Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Gynecologic Surgi

2007
A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery.
    Anesthesia and analgesia, 2007, Volume: 105, Issue:5

    Topics: Administration, Oral; Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Gynecologic Surgi

2007
Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:3

    Topics: Adolescent; Adult; Aged; Altitude Sickness; Amines; Cyclohexanecarboxylic Acids; Disorders of Excess

2008
High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.
    Epilepsy research, 1998, Volume: 29, Issue:2

    Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diarrhea; D

1998
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study.
    Epilepsia, 1999, Volume: 40, Issue:7

    Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Asthenia; Carbamazepine; Cycl

1999
Low doses of gabapentin may be helpful in the management of chronic daily headache.
    MedGenMed : Medscape general medicine, 2000, Aug-21, Volume: 2, Issue:3

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic

2000

Other Studies

21 other studies available for gamma-aminobutyric acid and Bilateral Headache

ArticleYear
Increased GABA+ in People With Migraine, Headache, and Pain Conditions- A Potential Marker of Pain.
    The journal of pain, 2021, Volume: 22, Issue:12

    Topics: Adult; Case-Control Studies; Chronic Pain; Cross-Sectional Studies; Female; gamma-Aminobutyric Acid;

2021
Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia.
    Pain, 2014, Volume: 155, Issue:5

    Topics: Animals; Dura Mater; gamma-Aminobutyric Acid; Glutamic Acid; Headache; Hyperalgesia; Male; Microdial

2014
Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia.
    Pain, 2014, Volume: 155, Issue:5

    Topics: Animals; Dura Mater; gamma-Aminobutyric Acid; Glutamic Acid; Headache; Hyperalgesia; Male; Microdial

2014
Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia.
    Pain, 2014, Volume: 155, Issue:5

    Topics: Animals; Dura Mater; gamma-Aminobutyric Acid; Glutamic Acid; Headache; Hyperalgesia; Male; Microdial

2014
Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia.
    Pain, 2014, Volume: 155, Issue:5

    Topics: Animals; Dura Mater; gamma-Aminobutyric Acid; Glutamic Acid; Headache; Hyperalgesia; Male; Microdial

2014
Nummular headache in a patient with ipsilateral occipital neuralgia--a case report.
    Neurologia i neurochirurgia polska, 2014, Volume: 48, Issue:2

    Topics: Amines; Analgesics; Anesthetics, Local; Bupivacaine; Comorbidity; Cyclohexanecarboxylic Acids; Femal

2014
Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus.
    Neurocritical care, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Amines; Analgesics; Aneurysm, Ruptured; Cyclohexanecarboxylic Acids; Female; Gabapentin

2015
Pressure pain sensitivity map of multifocal nummular headache: a case report.
    The journal of headache and pain, 2015, Volume: 16

    Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2015
Using a graphical risk tool to examine willingness to take migraine prophylactic medications.
    Pain, 2016, Volume: 157, Issue:10

    Topics: Amines; Analgesics; Antidepressive Agents; Antihypertensive Agents; Cross-Sectional Studies; Cyclohe

2016
Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache center.
    Internal and emergency medicine, 2008, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Autonomic Nervous System; Cyclohexanecarboxylic A

2008
Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:17

    Topics: 2-Aminopurine; Amines; Analgesics; Antiviral Agents; Comorbidity; Cyclohexanecarboxylic Acids; Famci

2012
[Case report on a patient with SUNCT-syndrome].
    Schmerz (Berlin, Germany), 2003, Volume: 17, Issue:2

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin

2003
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
    Neurology, 2003, May-13, Volume: 60, Issue:9

    Topics: Acetates; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Double-Blind Method; G

2003
Gabapentin-responsive idiopathic stabbing headache.
    Cephalalgia : an international journal of headache, 2004, Volume: 24, Issue:11

    Topics: Adolescent; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2004
Occipital neuralgia secondary to respiratory tract infection.
    Journal of orofacial pain, 2005,Summer, Volume: 19, Issue:3

    Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnos

2005
[Unique children -- unique headaches. Case reports of pediatric headache patients from an outpatient children's pain department].
    Schmerz (Berlin, Germany), 2006, Volume: 20, Issue:1

    Topics: Amines; Analgesics; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Developing Countries; Fema

2006
Nummular headache: first Italian case and therapeutic proposal.
    Cephalalgia : an international journal of headache, 2006, Volume: 26, Issue:3

    Topics: Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acids; Female; Ga

2006
Nummular headache: another case treated with gabapentin.
    The journal of headache and pain, 2007, Volume: 8, Issue:2

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2007
Occipital levels of GABA are related to severe headaches in migraine.
    Neurology, 2008, May-27, Volume: 70, Issue:22

    Topics: Adult; Cross-Sectional Studies; Female; gamma-Aminobutyric Acid; Headache; Humans; Magnetic Resonanc

2008
[Prophylactic treatment with gabapentin in chronic daily headache resistant to other drugs].
    Revista de neurologia, 1998, Volume: 26, Issue:153

    Topics: Acetates; Adult; Aged; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Resist

1998
An 8-year-old girl with unilateral facial and ear pain and isolated frontal headaches.
    Seminars in pediatric neurology, 1999, Volume: 6, Issue:3

    Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Earache; Face; Female

1999
SUNCT syndrome responsive to gabapentin (Neurontin).
    Cephalalgia : an international journal of headache, 2000, Volume: 20, Issue:5

    Topics: Acetates; Amines; Analgesics; Conjunctival Diseases; Cyclohexanecarboxylic Acids; Gabapentin; gamma-

2000
Cerebrospinal fluid gamma aminobutyric acid levels in migraine.
    British medical journal, 1975, Aug-30, Volume: 3, Issue:5982

    Topics: Aminobutyrates; gamma-Aminobutyric Acid; Headache; Humans; Migraine Disorders

1975
Platelet gamma-aminobutyric acid levels in migraine and tension-type headache.
    Headache, 1992, Volume: 32, Issue:5

    Topics: Adult; Blood Platelets; Female; gamma-Aminobutyric Acid; Headache; Humans; Male; Middle Aged; Migrai

1992